What the nay-sayers wrote since this morning were absolute LIES!!! Here are some facts:
(1) Gale sufficient cash and strong means to finance it operation for the future. The marketing of Abstral will further help to stabilize its financial position. Chapter 11 is totally NOT POSSIBLE!
(2) 12 financial analytical firms recently gave Gale a buy or outperform rating with an average target price of $4.75. I have listed these reputable firms in one of my recent messages on this board. The negative writers are LYING in broad daylight because they cannot give the name of company which they falsely claim to down-grade Gale.
(3) Gale can grow and develop on its own without the need of any buyout.
(4) NeuVax is a vaccine. Scientifically it just cannot mutate. Just like the well known flu vaccine which also never ever mutate. We expect the FDA to approve NeuVax soon because it has proven in Phase 1 & 2 to the satisfaction of the FDA that NeuVax is very safe with outstanding effectiveness in preventing breast cancer from returning and with very low side effects. In fact, FDA scientists collaborate with Gale scientists in establishing the parameters in carrying out the Phase 3 clinical trail for NeuVax.